Glaxosmithkline Biologicals Sa

Ribi Immunochem Research, Inc.

Corixa Corporation

Kent Raymond Myers

Chad Austin Farrenburg

Juan Jose Diaz Garcia

Jeb Yeatts Vandenburg

Ahmad Taimour Baig

Jeri Kay Sandvick

Felicie Georgette Colette Denet

Lora Lea Lawrence

Alex T Truchot

D Scott Snyder

Edgar F Ribi, Deceased

Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.

Saponin purification

Crude aqueous extracts ofMolina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is ≤0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.

Saponin extraction

Crude aqueous extracts ofMolina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is &#x2264;0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.

The invention relates to a method for extracting lipopolysaccharide (LPS) from rough trough mutant bacteria cells by extracting the cells with an aqueous aliphatic alcohol having from 1 to 4 carbon atoms at a temperature between 35 and 65 degrees C. to produce cells having a reduced phospholipid content. The resultant cells are then extracted with chloroform/methanol to yield LPS.

Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid A (3D-MLA)

Novel derivatives of monophosphoryl lipid A and a process for their preparation are provided. The derivatives contain one or more free groups, such as an amine, on a side chain attached to the primary hydroxyl groups of the monophosphoryl lipid A nucleus through an ester group. The derivatives provide a convenient method for coupling the lipid A through coupling agents to various biologically active materials, substrates, and the like, wherein the immunostimulant properties of lipid A are desired.

Derivatives of monophosphoryl lipid A

Modified lipopolysaccharides, particularly de-3-0-acylated monophosphoryl lipid A and de-3-0-acylated diphosphoryl lipid A, are provided by an alkaline hydrolysis under controlled conditions which removes only the .beta.-hydroxymyristic acyl residue that is ester-linked to the reducing-end glucosamine at position 3. The modified products are less endotoxic and maintain their antigenic and immuno-stimulating properties.

Growing community of inventors

Hamilton, MT, United States of America

Kent Raymond Myers